LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 1 | O20 | 72 | hr | 1401 | 3025 | 3978 | 0.7603 | 0.6671 |
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 2 | O20 | 72 | hr | 1401 | 3414 | 4213 | 0.8103 | 0.7519 |
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 3 | O20 | 72 | hr | 1401 | 3892 | 4545 | 0.8562 | 0.8251 |
| SK-BR-3 | Linsitinib | 10 | uM | LJP5 | 1 | O19 | 72 | hr | 1401 | 2789 | 3978 | 0.7010 | 0.5796 |
| SK-BR-3 | Linsitinib | 10 | uM | LJP5 | 2 | O19 | 72 | hr | 1401 | 3077 | 4213 | 0.7303 | 0.6409 |
| SK-BR-3 | Linsitinib | 10 | uM | LJP5 | 3 | O19 | 72 | hr | 1401 | 3359 | 4545 | 0.7389 | 0.6735 |
| SK-BR-3 | Ruxolitinib | 0.04 | uM | LJP5 | 1 | O18 | 72 | hr | 1401 | 3818 | 3978 | 0.9596 | 0.9460 |
| SK-BR-3 | Ruxolitinib | 0.04 | uM | LJP5 | 2 | O18 | 72 | hr | 1401 | 4274 | 4213 | 1.0144 | 1.0181 |
| SK-BR-3 | Ruxolitinib | 0.04 | uM | LJP5 | 3 | O18 | 72 | hr | 1401 | 4637 | 4545 | 1.0200 | 1.0235 |
| SK-BR-3 | Ruxolitinib | 0.12 | uM | LJP5 | 1 | O17 | 72 | hr | 1401 | 3996 | 3978 | 1.0044 | 1.0058 |
| SK-BR-3 | Ruxolitinib | 0.12 | uM | LJP5 | 2 | O17 | 72 | hr | 1401 | 4142 | 4213 | 0.9831 | 0.9786 |
| SK-BR-3 | Ruxolitinib | 0.12 | uM | LJP5 | 3 | O17 | 72 | hr | 1401 | 4595 | 4545 | 1.0108 | 1.0127 |
| SK-BR-3 | Ruxolitinib | 0.37 | uM | LJP5 | 1 | O16 | 72 | hr | 1401 | 3861 | 3978 | 0.9705 | 0.9605 |
| SK-BR-3 | Ruxolitinib | 0.37 | uM | LJP5 | 2 | O16 | 72 | hr | 1401 | 4534 | 4213 | 1.0761 | 1.0946 |
| SK-BR-3 | Ruxolitinib | 0.37 | uM | LJP5 | 3 | O16 | 72 | hr | 1401 | 4430 | 4545 | 0.9745 | 0.9698 |
| SK-BR-3 | Ruxolitinib | 1.11 | uM | LJP5 | 1 | O15 | 72 | hr | 1401 | 3901 | 3978 | 0.9805 | 0.9740 |
| SK-BR-3 | Ruxolitinib | 1.11 | uM | LJP5 | 2 | O15 | 72 | hr | 1401 | 4257 | 4213 | 1.0104 | 1.0130 |
| SK-BR-3 | Ruxolitinib | 1.11 | uM | LJP5 | 3 | O15 | 72 | hr | 1401 | 4189 | 4545 | 0.9215 | 0.9060 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 1 | O14 | 72 | hr | 1401 | 4046 | 3978 | 1.0169 | 1.0225 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 2 | O14 | 72 | hr | 1401 | 4605 | 4213 | 1.0930 | 1.1152 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 3 | O14 | 72 | hr | 1401 | 4404 | 4545 | 0.9688 | 0.9630 |
| SK-BR-3 | Ruxolitinib | 10 | uM | LJP5 | 1 | O13 | 72 | hr | 1401 | 3782 | 3978 | 0.9506 | 0.9338 |
| SK-BR-3 | Ruxolitinib | 10 | uM | LJP5 | 2 | O13 | 72 | hr | 1401 | 4130 | 4213 | 0.9802 | 0.9750 |
| SK-BR-3 | Ruxolitinib | 10 | uM | LJP5 | 3 | O13 | 72 | hr | 1401 | 3813 | 4545 | 0.8388 | 0.8032 |
| SK-BR-3 | Momelotinib | 0.04 | uM | LJP5 | 1 | P12 | 72 | hr | 1401 | 3888 | 3978 | 0.9772 | 0.9696 |